Inactive Instrument

iCAD Inc Stock Nasdaq

Equities

US44934S1078

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq
- USD - Intraday chart for iCAD Inc
Sales 2024 * 18.79M Sales 2025 * 23.63M Capitalization 34.26M
Net income 2024 * -6M Net income 2025 * -4M EV / Sales 2024 * 1.82 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.45 x
P/E ratio 2024 *
-5.57 x
P/E ratio 2025 *
-7.22 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.71%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 59 22-01-09
Director of Finance/CFO 49 21-01-31
Chief Operating Officer - 23-04-30
Members of the board TitleAgeSince
Chief Executive Officer 59 22-01-09
Director/Board Member 59 15-12-08
Director/Board Member 60 18-09-25
More insiders
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
More about the company